Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1NET 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 2fludarabine 2aldesleukin 2Nivolumab 2Ifosfamide 2Fluorodeoxyglucose F18 2Filgrastim 2Doxorubicin 2Cyclophosphamide 2trametinib 1tivozanib 1milademetan 1entrectinib 1dabrafenib 1cobimetinib 1berzosertib 1avelumab 1atezolizumab 1alectinib 1Vemurafenib 1Topotecan 1Taxes 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Magnetic Resonance Spectroscopy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × tivozanib × Endocrine × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡